



The EXACT-PRO “Expedition”: Mapping the PRO Instrument Qualification Trail

Nancy Kline Leidy PhD
United BioSource Corporation (UBC)

Presented at:

***FIRST ANNUAL
PATIENT-REPORTED OUTCOMES (PRO) CONSORTIUM
WORKSHOP***

March 23, 2010 – Bethesda, MD

Co-sponsored by




Acknowledgements



- Sponsors and sponsor representatives
 - 10+ sponsors and 20+ individuals
- Patients & clinical sites
 - 490 patients and 70 clinical sites
- Experts
 - 15 international, multi-disciplinary
- UBC Research Staff
 - 35+ international, multi-disciplinary

The EXACT-PRO “Expedition”: Mapping the PRO Instrument Qualification Trail





The “Expedition”



Why?

- Why did Lewis & Clark make this trip?
- How good a guide was Sacagawea?
- Did Lewis & Clark intend to discover the Pacific Ocean?
- Did other people accompany Lewis & Clark?
- How many people survived the trip?
- Who paid for the expedition?

How?


- How can anyone say Lewis & Clark “discovered” anything, since Native Americans living along their route already knew the places & creatures?
- Can I follow their exact route today?

Now?

The EXACT-PRO “Expedition”



- Why?
 - Background
- How?
 - Journey
- Now?
 - Current location
- Summary



Why?



- The EXACT-PRO Initiative
 - EXAcerbations of Chronic Pulmonary Disease Tool – Patient-Reported Outcome
- Purpose
 - Standardize measurement of frequency, severity, & duration of exacerbations of COPD
- Rationale
 - The initial detection of an exacerbation originates with symptoms known directly by the patient and clinical assessments are based on patient report to the clinician.
 - No standardized method for evaluating exacerbations in clinical trials.

Why?



- The presence of a PRO assessment problem
- Clearly named and described
- Sponsor & FDA interest & priority
- Timelines & resources

How?



- Identify a leader
- Clarify the concept
- Discuss concept with the Agency
- Identify sponsors
- Engage experts
- Assemble the research team

Experience

- Therapeutic area
 - Instrument development
 - Clinical trials

Reach Agreement



- Players
 - Sponsors, agency involvement, experts
- Purpose
 - Concept is important
 - There is a measurement issue that needs to be addressed
- Method
 - Scientific process & timelines
- Decision-making process
 - Responsible Principal Investigator

A Phased Approach



- Phase I
 - Literature review
 - Focus groups & interviews, item pool development
 - Cognitive debriefing
 - Expert participation
- Phase II
 - Validation study design, execution, SAP development
 - Analyses, interpretation
 - Expert participation
- Phase III
 - User manual, dossier development, dissemination, user guidance
- Phase IV
 - Translation, user guidance, instrument protection

Timelines (EXACT-PRO)





- Phase I - **7 months**
 - Literature review
 - Focus groups & interviews, Item pool development
 - Cognitive debriefing
 - Expert participation
- Phase II - **17 months**
 - Validation study design, execution, SAP development
 - Analyses, interpretation
 - Expert participation
- Phase III - **12 months**
 - User manual, dossier development, dissemination, user guidance
- Phase IV – **12 months**
 - Translation, user guidance, instrument protection


Trial Use

2+ Years


Milestones

- Concept & target claims
- Proposed approach 

- Literature review
- Qualitative protocol
- Qualitative results with draft instrument 

- Cognitive interviews with final items
- Validation study protocol 

- Validation study results

- Dossier submission 
- Qualification

Research Staff



Principal Investigator & Director
Co-Investigators

Types of Staff

- Project Managers, Associates, Research Assistants
- Data Managers
- Statisticians
 - IRT, Rasch; Biostatistics
- Statistical Programmers
- Production Assistants
- Meeting planning/logistics
- Information Technology
- Legal and finance

Expertise & Experience

- Therapeutic Area
- Regulatory Requirements
- Qualitative Methods
 - Interviews, Focus Groups
 - Analyses
- Quantitative Methods
 - Study Design
 - Statistical Analysis Plans
 - Analyses
 - Interpretation
- Report Preparation
 - Dossier

Experts & Expert Panels



- 2 clinical research/therapeutic experts
 - Consultation, document review, reality check
 - Telephone, in-person meetings
 - Small group expert-based decision making
- Additional experts*
 - Clinical area, clinical research
 - Instrument development
 - Regulatory issues
 - Sponsors
 - International considerations

*EXACT-PRO: Expert Panel Meetings

EXACT Expert Panel Meetings*



- #1 Concept, methods, qualitative results
 - Context of use, target sample, data
- #2 Qualitative results, draft items, validation protocol
 - Content validity, validation protocol designs
- #3 Quantitative results
 - Reliability, validity, responsiveness
- #4 Special issues
 - Scoring & interpretation, follow-up validation study

*Corresponding to milestones

Expert Panel Meetings



- Purpose & agenda
- Expert panel
 - Expertise-based exchange
 - Sponsor representation
- Observers
 - Additional FDA
 - Sponsors (2/company)
 - Opportunity for participation



FDA Involvement




- Informal
 - SEALD & review division input
 - Participation in expert panel meetings
 - At the table, regulatory considerations, exchange
 - Observer participants
 - Intervening agency dialogue
 - Focused - Specific purpose, agenda, slides, outcome
- Formal
 - Dossier submission and qualification review
- Recommendation
 - Formal milestones with review and feedback



Communication




- Sponsors, experts, FDA
 - Expert panel meetings
 - Web-site document access
 - E-mail updates
- Sponsors
 - E-mail newsletters
 - Conference calls
 - “1:1” conference calls – experts, sponsors
- Scientific community
 - National & international meetings
- Recommendation
 - Formal feedback from the FDA at milestones





Dissemination



- Subject the work to scientific review
- Open communication about the work
- Presentation -> publication
- Sponsor acknowledgement
- Authorship – Intellectual Work
 - PIs, experts, study group



Sponsorship



Maintenance




- User support
 - Sponsors, new pharma, academics
- New context/purpose
 - Adjustments in target population or setting
- Translations
 - Standardized translated versions
- Mode of administration
 - Changing electronic platforms
 - Equivalence testing
- Ongoing validation testing
 - Clinical studies, clinical trials, target populations

The EXACT-PRO “Expedition”



- Why?
 - Background
- How?
 - Journey
- Now?
 - Current location
- Summary



Now?



- Dossier Submitted to the FDA
 - December 2009
 - Contents:
 - Concept
 - Definition, conceptual framework, example endpoint models
 - Qualitative methods & results
 - Quantitative methods & results
 - Supportive documentation
- Awaiting Feedback

Current Location


Click a dot to learn about each national park along the Lewis and Clark Trail.



The EXACT-PRO “Expedition”



- Why?
 - Background
- How?
 - Journey
- Now?
 - Current location
- Summary



Summary



- Problem identification
 - Clarity & agreement
- Phased approach
 - Development, validation with milestones
- Research staff with dedicated time & broad expertise
 - Therapeutic, qualitative, quantitative
- Expert participation
 - Consultation & FDA feedback
- Communication
 - Sponsors, FDA, experts, community
- Dissemination
 - Presentations, publications
- Sponsorship
 - Continuous funding stream
- Maintenance
 - Use & ongoing validation work
- Dossier for qualification
 - Feedback & persistence



The “Expedition”



Why?

- Why did Lewis & Clark make this trip?
- How good a guide was Sacagawea?
- Did Lewis & Clark intend to discover the Pacific Ocean?
- Did other people accompany Lewis & Clark?
- How many people survived the trip?
- Who paid for the expedition?
- How can anyone say Lewis & Clark “discovered” anything, since Native Americans living along their route already knew the places & creatures?
- Can I follow their exact route today?

How?

Now?

With Time Comes Clarity

